The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NETs) who are not eligible to surgery or chemotherapy.
M. Martin-Richard
No relevant relationships to disclose
V. Alonso
No relevant relationships to disclose
M. Marmol
No relevant relationships to disclose
D. E. Castellano
No relevant relationships to disclose
E. Fonseca
No relevant relationships to disclose
A. Velasco
No relevant relationships to disclose
J. L. Garcia
No relevant relationships to disclose
F. Rivera
No relevant relationships to disclose
A. Galan
No relevant relationships to disclose
M. Quindos
No relevant relationships to disclose
I. Maetsu
No relevant relationships to disclose
P. Martinez de Prado
No relevant relationships to disclose
J. Sastre
No relevant relationships to disclose
M. Llanos
No relevant relationships to disclose
C. Pericay
No relevant relationships to disclose
A. Segura
No relevant relationships to disclose
J. Arenas
No relevant relationships to disclose
E. Pineda
No relevant relationships to disclose
P. Maisonobe
No relevant relationships to disclose
B. Massuti
No relevant relationships to disclose